224-RA IN MAN - LONG TERM EFFECTS ON BONE AND HAEMATOPOIETIC TISSUE
In an epidemiological study of the somatic late effects risk following incorporation of a short lived alpha-emitter, 1569 ankylosing spondylitis patients treated for their disease with repeated intraveneous injections of Ra-224 have been observed by the GSF. The usual injection scheme consisted of a total of 10-12 injections of 1.036 MBq each, given at weekly intervals; this is equivalent to an alpha-dose to the skeleton of 0.56-0.67 Gy for a 70-kg man. Causes of death have been ascertained in 483 patients in the exposure group and in 395 in the control group. By end of 1986 (mean follow-up times: 16.5 yr) three cases of malignant tumours in the skeleton have been observed (expected: 0.4-0.7) compared to no cases in the control group. One striking observation was that two of the three skeletal tumours observed in this study were tumours of the bone marrow in comparison with only one out of 55 observed by SPIESS "it et al". in their higher dose group. Diseases of haematopoietic tissue among living and dead patients included: anaemia or panmyelophthisis (11 in the exposure group vs. six in the control group), and leukaemia (six cases vs. five). In the control group most of the leukaemias were of the acute lymphatic type. There were no chronic myeloid leukaemias, even though three cases of the latter were observed in the exposure group. The incidence of myeloid leukaemias in relation to the alpha- dose rate is discussed from the literature.
Bibliographic Reference: 8TH INTERNATIONAL CONGRESS OF RADIATION RESEARCH, EDINBURGH/SCOTLAND, JULY 19-24, 1987, VOL. I, PP 210, PUBLISHED 1987, BY: TAYLOR AND FRANCIS, LONDON
Record Number: 1989126064900 / Last updated on: 1989-05-01
Available languages: en